人类 T 细胞白血病病毒 2 型的临床试验
总计5820个结果
-
Peking UniversityPeking University Cancer Hospital & Institute尚未招聘
-
Antengene Corporation招聘中
-
iCell Gene TherapeuticsPeking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.招聘中
-
Conjupro Biotherapeutics, Inc.CSPC ZhongQi Pharmaceutical Technology Co., Ltd.撤销
-
Eisai Co., Ltd.完全的
-
The University of Hong Kong未知
-
The First Affiliated Hospital of Soochow University未知
-
H. Lee Moffitt Cancer Center and Research InstituteSeagen Inc.终止
-
Nanfang Hospital of Southern Medical University未知
-
Kyowa Hakko Kirin Pharma, Inc.完全的
-
Novartis完全的
-
University Hospital, GrenobleFrench Innovative Leukemia Organisation完全的
-
Navy General Hospital, BeijingChinese PLA General Hospital招聘中
-
Sichuan Baili Pharmaceutical Co., Ltd.SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.招聘中
-
The Lymphoma Academic Research OrganisationCelgene主动,不招人复发性血管免疫母细胞性 T 细胞淋巴瘤 | 难治性血管免疫母细胞性 T 细胞淋巴瘤法国, 丹麦, 英国, 奥地利, 比利时
-
Fondazione Italiana Linfomi ONLUS主动,不招人
-
CelgeneCelgene Corporation完全的
-
Mundipharma (China) Pharmaceutical Co. Ltd完全的
-
Florida Academic Dermatology CentersCelgene Corporation未知
-
Xinhua Hospital, Shanghai Jiao Tong University...完全的
-
University of BirminghamCelgene; Amgen; Bloodwise完全的
-
National Cancer Centre, SingaporeBristol-Myers Squibb撤销
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.终止Relapsed Cutaneous T Cell Lymphom中国